朝聚眼科(02219)发布公告，郑程杰先生自2026年1月1日起已辞任公司的联席公司秘书职务，并自2026 年1月1日起已辞任香港联合交易所有限公司证券上市规则第3.05条所规定的公司授权代表及依据公司条 例(香港法例第622章)第16部项下代表公司在香港接收法律程序文件及通知的获授权代表(法律程序代 表)。罗伟健先生获委任为公司公司秘书、授权代表及法律程序代表，自2026年1月1日起生效。 ...

朝聚眼科(02219)发布公告，于2025年12月30日该公司斥资29.69万港元回购11万股，回购价格为每股 2.68-2.72港元。 ...

12月30日，华厦眼科跌1.04%，截至发稿，报18.01元/股，成交3656.19万元，换手率0.31%，总市值 151.28亿元。华厦眼科股价已经连续3天下跌，区间累计跌幅0.6%。 资料显示，华厦眼科医院集团股份有限公司位于福建省厦门市湖里区五通西路999号，成立日期2004年8 月12日，上市日期2022年11月7日，公司主营业务涉及眼科专科医疗服务。主营业务收入构成为：屈光 项目36.90%，眼视光综合项目24.04%，白内障项目20.14%，眼后段项目12.94%，其他(补充)5.99%。 数据显示，华宝基金旗下1只基金位居华厦眼科十大流通股东。华宝中证医疗ETF（512170）三季度减 持116.64万股，持有股数713.88万股，占流通股的比例为2.17%。根据测算，今日浮亏损失约135.64万 元。连续3天下跌期间浮亏损失78.53万元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模264.04亿。今年以来收益5.42%，同类 排名3760/4195；近一年收益3.14%，同类排名3826/4179；成立以来收益3.3%。 华宝中证医疗ETF（512170）基金经 ...

朝聚眼科(02219)发布公告，于2025年12月29日该公司斥资27.03万港元回购10万股，回购价格为每股 2.66-2.71港元。 ...

希玛医疗近期回购情况, 回购日期回购均价回购股数回购金额本年累计回购股数2025-12-191.65918.20万30.20万3001.20万2025- 12-181.61832.00万51.78万2983.00万2025-12-021.75016.00万28.01万2951.00万2025-12-011.75013.20万 23.10万2935.00万2025-11-281.73322.00万38.13万2921.80万2025-11-271.73012.00万20.76万2899.80万 2025-11-261.73216.00万27.72万2887.80万2025-11-251.72020.00万34.41万2871.80万2025-11-241.71220.00 万34.24万2851.80万2025-11-211.74024.00万41.76万2831.80万2025-11-201.80612.00万21.67万2807.80万 2025-11-191.80220.00万36.04万2795.80万2025-11-181.79216.00万28.67万2775.80万2025-11-171.8086 ...

Group 1 - The company, Chaoyue Eye Care (02219), announced a share buyback on December 11, 2025, for a total expenditure of HKD 320,300 [1] - A total of 120,000 shares will be repurchased at a price range of HKD 2.63 to HKD 2.70 per share [1]

证券日报网讯12月4日，华厦眼科（301267）在互动平台回答投资者提问时表示，公司长期专注于眼科 医疗服务，已经建立了全国连锁运营的诊疗服务体系。公司正按照发展战略规划，通过自建及并购方 式，稳步推进全国医疗服务网络布局。 ...

Core Viewpoint - The company, Chaoyue Eye Care (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 120,000 shares at a total cost of HKD 308,400 [1] - The buyback is scheduled for November 26, 2025, reflecting a strategic move to enhance shareholder value [1]

Core Viewpoint - The report highlights the significant growth in the number of myopia patients in China, indicating a rising demand for ophthalmic medical services and a robust market potential for eye care due to increasing health awareness and an aging population [1] Industry Summary - The number of myopia patients in China increased from 540 million in 2016 to 660 million in 2020, with the national myopia prevalence rising from 39.2% to 47.1% [1] - The demand for refractive surgery is expected to grow continuously as awareness of vision health increases and the number of myopia patients rises [1] - The aging population and enhanced health consciousness among the elderly are projected to expand the demand for cataract and other eye disease treatments, indicating a vast market potential for ophthalmic medical services [1] Company Summary - Huaxia Eye Hospital is recognized as a leading private ophthalmic medical enterprise in China, with strong academic capabilities and a clear expansion model [1] - The company is expected to maintain steady growth in performance, driven by the anticipated recovery in consumer healthcare, continuous upgrades in refractive surgical techniques, and increased demand for medical services due to aging trends [1] - Projected net profits for Huaxia Eye Hospital are estimated to reach 482 million, 552 million, and 629 million yuan for the years 2025, 2026, and 2027, respectively [1]

Core Viewpoint - The company, Chaoyue Eye Care (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company plans to repurchase 120,000 shares at a total cost of HKD 307,800 [1] - The buyback price per share ranges from HKD 2.55 to HKD 2.58 [1]